Zentalis Pharmaceuticals (ZNTL) Change in Accured Expenses (2019 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Change in Accured Expenses of -$1.5 million for Q1 2026, up 63.93% year-over-year from -$885121.0 in Q1 2025, and down 97.95% quarter-over-quarter from -$733000.0 in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) Change in Accured Expenses (2019 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$1.5 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 63.93% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at -$14.7 million (down 116.95% YoY), while the FY2025 annual figure was -$17.3 million, up 3.92% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$1.5 million, down from -$733000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $11.8 million in Q2 2024, with the low at -$15.2 million in Q1 2024.
- The 5-year median for Change in Accured Expenses is -$1.4 million (2023), against an average of -$608411.8.
- Peak annual rise in Change in Accured Expenses reached 368.48% in 2024, while the deepest fall reached 980.72% in 2024.
- Zentalis Pharmaceuticals' Change in Accured Expenses stood at $5.0 million in 2022, then soared by 105.88% to $10.4 million in 2023, then plunged by 124.64% to -$2.6 million in 2024, then jumped by 71.39% to -$733000.0 in 2025, then tumbled by 97.95% to -$1.5 million in 2026.
- Business Quant data shows ZNTL's Change in Accured Expenses at -$1.5 million in Q1 2026, -$733000.0 in Q4 2025, and -$2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | 2.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.26 Mn |
| Jun 30, 2026 | 2.26 Mn |
| Mar 31, 2026 | -1.45 Mn |
| Mar 31, 2026 | -1.45 Mn |
| Dec 31, 2025 | -733,000.00 |
| Dec 31, 2025 | -733,000.00 |
| Sep 30, 2025 | -1.98 Mn |
| Sep 30, 2025 | -1.98 Mn |
| Jun 30, 2025 | -10.58 Mn |
| Jun 30, 2025 | -10.58 Mn |
| Mar 31, 2025 | -4.02 Mn |
| Mar 31, 2025 | -4.02 Mn |
| Dec 31, 2024 | -2.56 Mn |
| Dec 31, 2024 | -2.56 Mn |
| Sep 30, 2024 | -12.01 Mn |
| Sep 30, 2024 | -12.01 Mn |
| Jun 30, 2024 | 11.80 Mn |
| Jun 30, 2024 | 11.80 Mn |
| Mar 31, 2024 | -15.25 Mn |
| Mar 31, 2024 | -15.25 Mn |